BAX vs CTSO: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

BAX is the larger of the two ($13.23B market cap): the incumbent the market prices for continued execution (12.50x forward earnings, beta 0.67). CTSO is the smaller challenger ($13.85M), priced similarly on forward earnings (∞x): more room to run, but more to prove. If you believe in growth, CTSO fits: analysts expect its revenue to rise 16% next year, against 2% for BAX. If you believe BAX's main driver (Margin and operational turnaround) matters more than the growth gap, BAX fits.

BAX vs CTSO: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricBAXCTSOWhat it tells you
Market cap$13.23B$13.85MSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E12.50∞Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Price vs 52-week range69% of range11% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.

Before you buy: how BAX and CTSO affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BAX and CTSO share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BAX and CTSO exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Baxter International (BAX) do?

Baxter International makes essential hospital and critical-care products, including IV solutions, infusion pumps (the Novum IQ and legacy platforms), premixed and injectable drugs, surgical sealants, and connected-care hardware from the Hillrom acquisition. After decades as a sprawling healthcare conglomerate, Baxter reshaped itself: it spun off and then sold its Kidney Care segment (rebranded Vantive) to Carlyle for roughly $3.8 billion, using proceeds to reduce debt. What remains is a company centered on Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals, serving hospitals worldwide with high-volume, mission-critical supplies.

Full BAX guide

What does CytoSorbents Corporation (CTSO) do?

CytoSorbents makes porous polymer beads packed into cartridges that clip into a blood circuit and pull inflammatory molecules, toxins and some drugs out of a patient's blood. Its main product, CytoSorb, is approved in the European Union and distributed in more than 70 countries, where intensive care units use it in septic shock and cardiac surgeons use it during bypass procedures. The company also owns DrugSorb-ATR, a version aimed at removing the blood thinner Brilinta (ticagrelor) during urgent heart surgery, which is not yet authorized in the United States, and HemoDefend-BGA, an early program meant to make universal plasma. Nearly all revenue comes from outside the U.S.: in the third quarter of 2026 American sales were about $70,000 out of $9.7 million.

Full CTSO guide

BAX vs CTSO: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • BAX drivers: Margin and operational turnaround; Deleveraging after the Vantive sale.
  • CTSO drivers: Operating cash flow at breakeven; Returning CytoSorb to growth.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The Novum LVP pump shipment hold was expected to persist through the year with no committed resolution timeline, pressuring both revenue and profit. For CTSO, financing is still the largest risk, though the November 2026 deal changed its shape.

BAX or CTSO: which should you pick?

If the story you believe is BAX's (Margin and operational turnaround), BAX is the more direct way to own it; if it is CTSO's (Operating cash flow at breakeven), CTSO is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BAX and CTSO guides.

BAX vs CTSO: the full fundamentals

BAX. Baxter trades at about 12.5 times forward earnings and roughly 1.1 times sales, a modest valuation for medtech that reflects its low-growth profile and the debt load, even after a 31% rally in 2026. Reported GAAP profit is still negative over the trailing year because of special charges, so adjusted metrics carry most of the weight; consensus looks for about $0.60 of EPS in the fourth quarter and about $2.05 for 2027, roughly flat with the 2026 guidance range.

CTSO. At ~$4.39 the stock trades at roughly 0.4 times trailing sales, a level usually seen in medical device companies with serious balance sheet problems. Earnings ratios do not apply: trailing net loss is ~$16.9 million, much of it from non-cash currency swings and interest, and analysts expect a ~-$3.72 per-share loss for 2026. The November 2026 amendment cut the Avenue loan to ~$12.25 million and moved the maturity to July 2028, so the valuation now rests more on whether a business near cash breakeven with ~73-75% gross margins can grow toward the ~$44 million of 2027 revenue analysts forecast.

Headline figures (approximate, November 2026): BAX shows revenue (ttm) ~$11.6B, q3 2026 sales ~$2.98B, up ~5% year over year, q3 2026 adjusted eps ~$0.58 vs ~$0.52 expected (down ~16% YoY), 2026 adjusted eps guidance $2.05-2.15 (raised Oct 29, from $1.95-2.15); CTSO shows revenue (ttm) ~$37.5 million, revenue growth (q3 2026, yoy) ~+2.6%, gross margin (ttm) ~73%, net loss (ttm) ~-$16.9 million.

The bottom line: BAX vs CTSO

BAX and CTSO are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined BAX and CTSO exposure against your real portfolio. It is not an investment adviser.

Wondering how BAX or CTSO fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Baxter International

Ask Walnut's AI anything about BAX and see how it fits what you own.

FAQ

What is the difference between BAX and CTSO?

+

Baxter International makes essential hospital and critical-care products, including IV solutions, infusion pumps (the Novum IQ and legacy platforms), premixed and injectable drugs, surgical sealants, and connected-care hardware from the Hillrom acquisition. CytoSorbents makes porous polymer beads packed into cartridges that clip into a blood circuit and pull inflammatory molecules, toxins and some drugs out of a patient's blood. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is BAX or CTSO the better stock?

+

Neither is universally better. BAX is the larger incumbent; CTSO is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, BAX or CTSO?

+

A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both BAX and CTSO?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of BAX vs CTSO?

+

BAX: The Novum LVP pump shipment hold was expected to persist through the year with no committed resolution timeline, pressuring both revenue and profit. Elevated debt (around $8.8 billion in total as of September 2026) constrains flexibility and makes the company sensitive to interest costs. Margins have been hit by special charges, injectable supply constraints, inflation, recall- and hurricane-related items, and tariff exposure, and the company still shows a GAAP net loss of roughly $619 million over the trailing twelve months. The FDA issued a warning letter dated September 29, 2026 citing manufacturing-practice violations at one US drug manufacturing site, and the end of transition-services fees from the kidney care sale in January 2027 removes a source of income. Competition from Becton Dickinson, ICU Medical, B. Braun, and Fresenius Kabi is intense across infusion and IV products. After a 31% rally this year, Wall Street's average rating is hold, and the average target of about $27.25 across 12 analysts sits only modestly above the share price. The turnaround is early and could take longer than management projects. CTSO: Financing is still the largest risk, though the November 2026 deal changed its shape. Avenue Capital debt fell from ~$17.5 million to ~$12.25 million, interest-only payments were extended to March 31, 2028 (three more months if DrugSorb-ATR is approved by then) and maturity moved to July 1, 2028; the company puts interest savings at ~$0.7 million over twelve months. Avenue can now convert up to ~$3.0 million of principal at $6.916 a share, and another ~$3.125 million at $8.645 from the earlier of DrugSorb-ATR approval or January 1, 2028, so further dilution is built in. Most of the ~$4.0 million of new cash went to repaying ~$3.0 million of principal plus fees, which leaves the company relying on breakeven operations. Listing is the second risk: the market value is far below Nasdaq's $35 million minimum, the December 28, 2026 deadline is close, and the new shares add equity but the company itself says there is no assurance it keeps the listing. Accounting is a third: material weaknesses persist, and the Q3 10-Q was filed late after a currency loss error; the first release understated nine-month net loss by ~$0.6 million. Regulatory risk remains, because the FDA has already turned down DrugSorb-ATR once, and the business depends heavily on German and European hospital budgets.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell BAX or CTSO; figures are approximate and dated (as of November 2026). Verify current data before investing.